Vicent CasadÃ³

List of Publications by Year
in descending order

139 papers	10,518 citations	23567 58 h-index	34986 98 g-index
140 all docs	140 docs citations	140 times ranked	7876 citing authors

#	Article	IF	Citations
1	Heterobivalent Ligand for the Adenosine A_{2A}â€“Dopamine D₂ Receptor Heteromer. Journal of Medicinal Chemistry, 2022, 65, 616-632.	6.4	13
2	Complexes of Ghrelin GHS-R1a, GHS-R1b, and Dopamine D₁Receptors Localized in the Ventral Tegmental Area as Main Mediators of the Dopaminergic Effects of Ghrelin. Journal of Neuroscience, 2022, 42, 940-953.	3.6	10
3	Unmasking allosteric-binding sites: novel targets for GPCR drug discovery. Expert Opinion on Drug Discovery, 2022, 17, 897-923.	5.0	7
4	Preferential Gs protein coupling of the galanin Gal1 receptor in the Âµ-opioid-Gal1 receptor heterotetramer. Pharmacological Research, 2022, 182, 106322.	7.1	11
5	Orally Active Peptide Vector Allows Using Cannabis to Fight Pain While Avoiding Side Effects. Journal of Medicinal Chemistry, 2021, 64, 6937-6948.	6.4	9
6	Heteromerization between Î±2A adrenoceptors and different polymorphic variants of the dopamine D4 receptor determines pharmacological and functional differences. Implications for impulsive-control disorders. Pharmacological Research, 2021, 170, 105745.	7.1	6
7	Identification of BiP as a CB₁ Receptor-Interacting Protein That Fine-Tunes Cannabinoid Signaling in the Mouse Brain. Journal of Neuroscience, 2021, 41, 7924-7941.	3.6	14
8	Oligomerization of G protein-coupled receptors: Still doubted?. Progress in Molecular Biology and Translational Science, 2020, 169, 297-321.	1.7	20
9	Control of glutamate release by complexes of adenosine and cannabinoid receptors. BMC Biology, 2020, 18, 9.	3.8	51
10	Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use. Schizophrenia Bulletin, 2020, 46, 1547-1557.	4.3	17
11	Modulation of dopamine D1 receptors via histamine H3 receptors is a novel therapeutic target for Huntington's disease. ELife, 2020, 9, .	6.0	20
12	Adenosine A1-Dopamine D1 Receptor Heteromers Control the Excitability of the Spinal Motoneuron. Molecular Neurobiology, 2019, 56, 797-811.	4.0	36
13	Targeting the receptor-based interactome of the dopamine D1 receptor: looking for heteromer-selective drugs. Expert Opinion on Drug Discovery, 2019, 14, 1297-1312.	5.0	7
14	Biased G Protein-Independent Signaling of Dopamine D1-D3 Receptor Heteromers in the Nucleus Accumbens. Molecular Neurobiology, 2019, 56, 6756-6769.	4.0	33
15	The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?. Frontiers in Pharmacology, 2019, 10, 339.	3.5	91
16	Therapeutic targeting of HER2â€“CB ₂ R heteromers in HER2-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3863-3872.	7.1	40
17	The heterotetrameric structure of the adenosine A1-dopamine D1 receptor complex: Pharmacological implication for restless legs syndrome. Advances in Pharmacology, 2019, 84, 37-78.	2.0	8
18	Reinterpreting anomalous competitive binding experiments within G protein-coupled receptor homodimers using a dimer receptor model. Pharmacological Research, 2019, 139, 337-347.	7.1	15

#	Article	IF	Citations
19	Revisiting the Functional Role of Dopamine D4 Receptor Gene Polymorphisms: Heteromerization-Dependent Gain of Function of the D4.7 Receptor Variant. Molecular Neurobiology, 2019, 56, 4778-4785.	4.0	13
20	Opioidâ€"galanin receptor heteromers mediate the dopaminergic effects of opioids. Journal of Clinical Investigation, 2019, 129, 2730-2744.	8.2	41
21	Cannabis Users Show Enhanced Expression of CB1-5HT2A Receptor Heteromers in Olfactory Neuroepithelium Cells. Molecular Neurobiology, 2018, 55, 6347-6361.	4.0	34
22	Î±2A- and Î±2C-Adrenoceptors as Potential Targets for Dopamine and Dopamine Receptor Ligands. Molecular Neurobiology, 2018, 55, 8438-8454.	4.0	26
23	Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum. Neuropsychopharmacology, 2018, 43, 964-977.	5.4	52
24	Design of a True Bivalent Ligand with Picomolar Binding Affinity for a G Protein-Coupled Receptor Homodimer. Journal of Medicinal Chemistry, 2018, 61, 9335-9346.	6.4	34
25	Molecular Evidence of Adenosine Deaminase Linking Adenosine A2A Receptor and CD26 Proteins. Frontiers in Pharmacology, 2018, 9, 106.	3.5	54
26	Essential Control of the Function of the Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A2A-Dopamine D2 Receptor Heterotetramers and Adenylyl Cyclase. Frontiers in Pharmacology, 2018, 9, 243.	3.5	73
27	Cross-communication between Gi and Gs in a G-protein-coupled receptor heterotetramer guided by a receptor C-terminal domain. BMC Biology, 2018, 16, 24.	3.8	70
28	Evidence for functional pre-coupled complexes of receptor heteromers and adenylyl cyclase. Nature Communications, 2018, 9, 1242.	12.8	103
29	Heteroreceptor Complexes Formed by Dopamine D1, Histamine H3, and N-Methyl-D-Aspartate Glutamate Receptors as Targets to Prevent Neuronal Death in Alzheimerâ€™s Disease. Molecular Neurobiology, 2017, 54, 4537-4550.	4.0	44
30	Functional Î¼-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area. Journal of Neuroscience, 2017, 37, 1176-1186.	3.6	34
31	Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome. Frontiers in Neuroscience, 2017, 11, 722.	2.8	64
32	Caffeine, Adenosine A 1 Receptors, and Brain Cortex. Molecular Aspects. , 2016, , 741-752.		0
33	A Significant Role of the Truncated Ghrelin Receptor GHS-R1b in Ghrelin-induced Signaling in Neurons. Journal of Biological Chemistry, 2016, 291, 13048-13062.	3.4	41
34	Targeting the dopamine D3 receptor: an overview of drug design strategies. Expert Opinion on Drug Discovery, 2016, 11, 641-664.	5.0	49
35	Evidence for the heterotetrameric structure of the adenosine A2Aâ€"dopamine D2 receptor complex. Biochemical Society Transactions, 2016, 44, 595-600.	3.4	31
36	Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease. Neurobiology of Disease, 2016, 96, 47-53.	4.4	21

#	Article	IF	Citations
37	Quaternary structure of a G-protein-coupled receptor heterotetramer in complex with Gi and Gs. BMC Biology, 2016, 14, 26.	3.8	97
38	Allosteric mechanisms within the adenosine A2Aâ€“dopamine D2 receptor heterotetramer. Neuropharmacology, 2016, 104, 154-160.	4.1	77
39	Hints on the Lateralization of Dopamine Binding to D1 Receptors in Rat Striatum. Molecular Neurobiology, 2016, 53, 5436-5445.	4.0	7
40	A solid-phase combinatorial approach for indoloquinolizidine-peptides with high affinity at D1 and D2 dopamine receptors. European Journal of Medicinal Chemistry, 2015, 97, 173-180.	5.5	11
41	Allosteric interactions between agonists and antagonists within the adenosine A _{2A} receptor-dopamine D ₂ receptor heterotetramer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3609-18.	7.1	135
42	Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain. Translational Psychiatry, 2015, 5, e549-e549.	4.8	106
43	Orexinâ€“Corticotropin-Releasing Factor Receptor Heteromers in the Ventral Tegmental Area as Targets for Cocaine. Journal of Neuroscience, 2015, 35, 6639-6653.	3.6	66
44	Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia. Molecular Neurobiology, 2015, 52, 1408-1420.	4.0	49
45	Moonlighting Adenosine Deaminase: A Target Protein for Drug Development. Medicinal Research Reviews, 2015, 35, 85-125.	10.5	54
46	Allosteric Mechanisms in the Adenosine A2A-Dopamine D2 Receptor Heteromer. Current Topics in Neurotoxicity, 2015, , 27-38.	0.4	0
47	Functional Selectivity of Allosteric Interactions within G Proteinâ€“Coupled Receptor Oligomers: The Dopamine D₁-D₃ Receptor Heterotetramer. Molecular Pharmacology, 2014, 86, 417-429.	2.3	114
48	Cocaine Disrupts Histamine H₃Receptor Modulation of Dopamine D₁Receptor Signaling: Ïƒ₁-D₁-H₃Receptor Complexes as Key Targets for Reducing Cocaine's Effects. Journal of Neuroscience, 2014, 34, 3545-3558.	3.6	66
49	Intracellular Calcium Levels Determine Differential Modulation of Allosteric Interactions within G Protein-Coupled Receptor Heteromers. Chemistry and Biology, 2014, 21, 1546-1556.	6.0	51
50	Gâ€Proteinâ€Coupled Receptor Heteromers as Key Players in the Molecular Architecture of the Central Nervous System. CNS Neuroscience and Therapeutics, 2014, 20, 703-709.	3.9	23
51	l-DOPA-treatment in primates disrupts the expression of A2A adenosineâ€“CB1 cannabinoidâ€“D2 dopamine receptor heteromers in the caudate nucleus. Neuropharmacology, 2014, 79, 90-100.	4.1	83
52	G Proteinâ€“Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives. Pharmacological Reviews, 2014, 66, 413-434.	16.0	497
53	l-DOPA disrupts adenosine A2Aâ€“cannabinoid CB1â€“dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies. Experimental Neurology, 2014, 253, 180-191.	4.1	77
54	A1Râ€“A2AR heteromers coupled to Gs and Gi/0 proteins modulate GABA transport into astrocytes. Purinergic Signalling, 2013, 9, 433-449.	2.2	123

#	Article	IF	Citations
55	The catalytic site structural gate of adenosine deaminase allosterically modulates ligand binding to adenosine receptors. FASEB Journal, 2013, 27, 1048-1061.	0.5	35
56	Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans. Neuropharmacology, 2013, 67, 476-484.	4.1	64
57	Homodimerization of adenosine A1 receptors in brain cortex explains the biphasic effects of caffeine. Neuropharmacology, 2013, 71, 56-69.	4.1	30
58	Detection of Receptor Heteromers Involving Dopamine Receptors by the Sequential BRET-FRET Technology. Methods in Molecular Biology, 2013, 964, 95-105.	0.9	10
59	Cocaine Inhibits Dopamine D2 Receptor Signaling via Sigma-1-D2 Receptor Heteromers. PLoS ONE, 2013, 8, e61245.	2.5	112
60	Circadian-Related Heteromerization of Adrenergic and Dopamine D4 Receptors Modulates Melatonin Synthesis and Release in the Pineal Gland. PLoS Biology, 2012, 10, e1001347.	5.6	132
61	Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain. Journal of Biological Chemistry, 2012, 287, 20851-20865.	3.4	196
62	NCS-1 associates with adenosine A2A receptors and modulates receptor function. Frontiers in Molecular Neuroscience, 2012, 5, 53.	2.9	46
63	A new D2 dopamine receptor agonist allosterically modulates A2A adenosine receptor signalling by interacting with the A2A/D2 receptor heteromer. Cellular Signalling, 2012, 24, 951-960.	3.6	16
64	Biotin Ergopeptide Probes for Dopamine Receptors. Journal of Medicinal Chemistry, 2011, 54, 1080-1090.	6.4	13
65	Modulation of GABA Transport by Adenosine A1R-A2AR Heteromers, Which Are Coupled to Both Gs- and Gi/o-Proteins. Journal of Neuroscience, 2011, 31, 15629-15639.	3.6	16
66	Real-Time G-Protein-Coupled Receptor Imaging to Understand and Quantify Receptor Dynamics. Scientific World Journal, The, 2011, 11, 1995-2010.	2.1	2
67	A2A adenosine receptor ligand binding and signalling is allosterically modulated by adenosine deaminase. Biochemical Journal, 2011, 435, 701-709.	3.7	37
68	Adenosine A2A Receptors and A2A Receptor Heteromers as Key Players in Striatal Function. Frontiers in Neuroanatomy, 2011, 5, 36.	1.7	44
69	Post-translational Membrane Insertion of Tail-anchored Transmembrane EF-hand Ca2+ Sensor Calneurons Requires the TRC40/Asna1 Protein Chaperone. Journal of Biological Chemistry, 2011, 286, 36762-36776.	3.4	28
70	Abnormal calcium handling in atrial fibrillation is linked to up-regulation of adenosine A2A receptors. European Heart Journal, 2011, 32, 721-729.	2.2	67
71	Dopamine D1-histamine H3 Receptor Heteromers Provide a Selective Link to MAPK Signaling in GABAergic Neurons of the Direct Striatal Pathway. Journal of Biological Chemistry, 2011, 286, 5846-5854.	3.4	109
72	Striatal Pre- and Postsynaptic Profile of Adenosine A2A Receptor Antagonists. PLoS ONE, 2011, 6, e16088.	2.5	115

#	Article	IF	Citations
73	G_i protein coupling to adenosine A₁â€“A_{2A} receptor heteromers in human brain caudate nucleus. Journal of Neurochemistry, 2010, 114, 972-980.	3.9	14
74	A Hybrid Indoloquinolizidine Peptide as Allosteric Modulator of Dopamine D1 Receptors. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 876-885.	2.5	13
75	Direct involvement of Ïƒ-1 receptors in the dopamine D ₁ receptor-mediated effects of cocaine. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18676-18681.	7.1	153
76	Interactions between Intracellular Domains as Key Determinants of the Quaternary Structure and Function of Receptor Heteromers. Journal of Biological Chemistry, 2010, 285, 27346-27359.	3.4	102
77	Platforms for the identification of GPCR targets, and of orthosteric and allosteric modulators. Expert Opinion on Drug Discovery, 2010, 5, 391-403.	5.0	6
78	G Protein-Coupled Receptor Heteromers as New Targets for Drug Development. Progress in Molecular Biology and Translational Science, 2010, 91, 41-52.	1.7	46
79	Interactions between Calmodulin, Adenosine A2A, and Dopamine D2 Receptors. Journal of Biological Chemistry, 2009, 284, 28058-28068.	3.4	65
80	GPCR homomers and heteromers: A better choice as targets for drug development than GPCR monomers?. , 2009, 124, 248-257.		84
81	Useful pharmacological parameters for G-protein-coupled receptor homodimers obtained from competition experiments. Agonistâ€“antagonist binding modulation. Biochemical Pharmacology, 2009, 78, 1456-1463.	4.4	39
82	Indoloquinolizidineâ€“Peptide Hybrids as Multiple Agonists for D₁ and D₂ Dopamine Receptors. ChemMedChem, 2009, 4, 1514-1522.	3.2	16
83	Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology, 2009, 206, 313-324.	3.1	108
84	Marked changes in signal transduction upon heteromerization of dopamine D₁ and histamine H₃ receptors. British Journal of Pharmacology, 2009, 157, 64-75.	5.4	138
85	Adenosine A_{2A} Receptor-Antagonist/Dopamine D₂ Receptor-Agonist Bivalent Ligands as Pharmacological Tools to Detect A_{2A}-D₂ Receptor Heteromers. Journal of Medicinal Chemistry, 2009, 52, 5590-5602.	6.4	129
86	Gâ€proteinâ€coupled receptor heteromers: function and ligand pharmacology. British Journal of Pharmacology, 2008, 153, S90-8.	5.4	60
87	Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nature Methods, 2008, 5, 727-733.	19.0	269
88	Human adenosine deaminase as an allosteric modulator of human A₁ adenosine receptor: abolishment of negative cooperativity for [³H](R)â€pia binding to the caudate nucleus. Journal of Neurochemistry, 2008, 107, 161-170.	3.9	45
89	Novel pharmacological targets based on receptor heteromers. Brain Research Reviews, 2008, 58, 475-482.	9.0	32
90	Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology, 2008, 55, 190-197.	4.1	157

#	Article	IF	Citations
91	Identification of Dopamine D1â€“D3 Receptor Heteromers. Journal of Biological Chemistry, 2008, 283, 26016-26025.	3.4	216
92	Detection of Heteromers Formed by Cannabinoid CB₁, Dopamine D₂, and Adenosine A_{2A}G-Protein-Coupled Receptors by Combining Bimolecular Fluorescence Complementation and Bioluminescence Energy Transfer. Scientific World Journal, The, 2008, 8, 1088-1097.	2.1	105
93	Reply: Does the adenosine A2A receptor stimulate the ryanodine receptor?. Cardiovascular Research, 2007, 73, 249-250.	3.8	2
94	Novel Ergopeptides as Dual Ligands for Adenosine and Dopamine Receptors. Journal of Medicinal Chemistry, 2007, 50, 3062-3069.	6.4	39
95	Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes that Mediate the Motor Effects of Cannabinoids. Neuropsychopharmacology, 2007, 32, 2249-2259.	5.4	229
96	Basic Concepts in G-Protein-Coupled Receptor Homo- and Heterodimerization. Scientific World Journal, The, 2007, 7, 48-57.	2.1	83
97	Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monomeric and dimeric receptors: The receptorâ€“dimer cooperativity index. , 2007, 116, 343-354.		70
98	Receptorâ€“receptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins. Journal of Neural Transmission, 2007, 114, 93-104.	2.8	69
99	Allosteric Modulation of Dopamine D2Receptors by Homocysteine. Journal of Proteome Research, 2006, 5, 3077-3083.	3.7	53
100	Heterodimeric adenosine receptors: a device to regulate neurotransmitter release. Cellular and Molecular Life Sciences, 2006, 63, 2427-2431.	5.4	88
101	Adenosine A2A receptors are expressed in human atrial myocytes and modulate spontaneous sarcoplasmic reticulum calcium release. Cardiovascular Research, 2006, 72, 292-302.	3.8	62
102	The Two-State Dimer Receptor Model: A General Model for Receptor Dimers. Molecular Pharmacology, 2006, 69, 1905-1912.	2.3	76
103	Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1-A2A Receptor Heteromers. Journal of Neuroscience, 2006, 26, 2080-2087.	3.6	553
104	Partners for Adenosine A₁ Receptors. Journal of Molecular Neuroscience, 2005, 26, 221-232.	2.3	25
105	Heptaspanning Membrane Receptors and Cytoskeletal/Scaffolding Proteins: Focus on Adenosine, Dopamine, and Metabotropic Glutamate Receptor Function. Journal of Molecular Neuroscience, 2005, 26, 277-292.	2.3	25
106	Molecular mechanisms involved in the adenosine A1 and A2A receptor-induced neuronal differentiation in neuroblastoma cells and striatal primary cultures. Journal of Neurochemistry, 2005, 92, 337-348.	3.9	56
107	Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. Journal of Neurochemistry, 2005, 95, 919-929.	3.9	140
108	Dimer-based model for heptaspanning membrane receptors. Trends in Biochemical Sciences, 2005, 30, 360-366.	7.5	60

#	Article	IF	Citations
109	ATP-Sensitive K + Channels Regulate the Concentrative Adenosine Transporter CNT2 following Activation by A 1 Adenosine Receptors. Molecular and Cellular Biology, 2004, 24, 2710-2719.	2.3	51
110	Group I Metabotropic Glutamate Receptors Mediate a Dual Role of Glutamate in T Cell Activation. Journal of Biological Chemistry, 2004, 279, 33352-33358.	3.4	113
111	Up-regulation of the Kv3.4 potassium channel subunit in early stages of Alzheimer's disease. Journal of Neurochemistry, 2004, 91, 547-557.	3.9	78
112	Combining Mass Spectrometry and Pull-Down Techniques for the Study of Receptor Heteromerization. Direct Epitopeâˆ'Epitope Electrostatic Interactions between Adenosine A2Aand Dopamine D2Receptors. Analytical Chemistry, 2004, 76, 5354-5363.	6.5	195
113	Adenosine A2A-dopamine D2 receptorâ€"receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism and Related Disorders, 2004, 10, 265-271.	2.2	132
114	Regulation of heptaspanning-membrane-receptor function by dimerization and clustering. Trends in Biochemical Sciences, 2003, 28, 238-243.	7.5	74
115	A₁ Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer's Disease and Mediate Both Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation. Brain Pathology, 2003, 13, 440-451.	4.1	150
116	Coaggregation, Cointernalization, and Codesensitization of Adenosine A2A Receptors and Dopamine D2Receptors. Journal of Biological Chemistry, 2002, 277, 18091-18097.	3.4	450
117	Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11940-11945.	7.1	345
118	Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminaseâ€'CD26 interaction. Biochemical Journal, 2002, 361, 203.	3.7	34
119	Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminaseâ€"CD26 interaction. Biochemical Journal, 2002, 361, 203-209.	3.7	57
120	Involvement of Caveolin in Ligand-Induced Recruitment and Internalization of A₁Adenosine Receptor and Adenosine Deaminase in an Epithelial Cell Line. Molecular Pharmacology, 2001, 59, 1314-1323.	2.3	84
121	Adenosine/dopamine receptor-receptor interactions in the central nervous system. Drug Development Research, 2001, 52, 296-302.	2.9	11
122	Metabotropic Glutamate 1Î± and Adenosine A1 Receptors Assemble into Functionally Interacting Complexes. Journal of Biological Chemistry, 2001, 276, 18345-18351.	3.4	170
123	Evidence for Adenosine/Dopamine Receptor Interactions Indications for Heteromerization. Neuropsychopharmacology, 2000, 23, S50-S59.	5.4	147
124	Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8606-8611.	7.1	419
125	The Heat Shock Cognate Protein hsc73 Assembles with A 1 Adenosine Receptors To Form Functional Modules in the Cell Membrane. Molecular and Cellular Biology, 2000, 20, 5164-5174.	2.3	62
126	Ecto-adenosine deaminase: An ecto-enzyme and a costimulatory protein acting on a variety of cell surface receptors. , 1998, 45, 261-268.		12

#	Article	IF	Citations
127	Cell surface adenosine deaminase: Much more than an ectoenzyme. Progress in Neurobiology, 1997, 52, 283-294.	5.7	224
128	The Cluster-Arranged Cooperative Model:Â A Model That Accounts for the Kinetics of Binding to A1Adenosine Receptorsâ€. Biochemistry, 1996, 35, 3007-3015.	2.5	38
129	Adenosine Deaminase Interacts with A₁ Adenosine Receptors in Pig Brain Cortical Membranes. Journal of Neurochemistry, 1996, 66, 1675-1682.	3.9	58
130	Immunological identification of A1adenosine receptors in brain cortex. Journal of Neuroscience Research, 1995, 42, 818-828.	2.9	121
131	A1 Adenosine receptors can occur manifesting two kinetic components of 8-cyclopentyl-1,3-[3H]dipropylxanthine ([3H]DPCPX) binding. Naunyn-Schmiedeberg's Archives of Pharmacology, 1994, 349, 485-491.	3.0	2
132	Role of Histidine Residues in Agonist and Antagonist Binding Sites of A1Adenosine Receptor. Journal of Neurochemistry, 1993, 60, 1525-1533.	3.9	10
133	The distribution of A1 adenosine receptor and 5?-nucleotidase in pig brain cortex subcellular fractions. Neurochemical Research, 1992, 17, 129-139.	3.3	10
134	The Adenosine Receptors Present on the Plasma Membrane of Chromaffin Cells Are of the A2bSubtype. Journal of Neurochemistry, 1992, 59, 425-431.	3.9	32
135	Modulation of adenosine agonist [3H]N6-(R)-phenylisopropyladenosine binding to pig brain cortical membranes by changes of membrane fluidity and of medium physicochemical characteristics. European Journal of Pharmacology, 1992, 225, 7-14.	2.6	15
136	Effect of phospholipases and proteases on the [3H]N6-(R)-phenylisopropyladenosine ([3H]R-PIA) binding to A1 adenosine receptors from pig cerebral cortex. Journal of Cellular Biochemistry, 1991, 47, 278-288.	2.6	13
137	Distribution of A1-adenosine receptors, adenosine deaminase and 5â€²-nucleotidase in brain and other tissues of the pig. Biochemical Society Transactions, 1990, 18, 639-641.	3.4	2
138	Solubilization of A1adenosine receptor from pig brain: Characterization and evidence of the role of the cell membrane on the coexistence of high- and low-affinity states. Journal of Neuroscience Research, 1990, 26, 461-473.	2.9	64
139	A method for binding parameters estimation of A1 adenosine receptor subtype: A practical approach. Analytical Biochemistry, 1990, 184, 117-123.	2.4	18